Deep learning framework for peak detection at the intact level of therapeutic proteins

Abstract

While automated peak detection functionalities are available in commercially accessible software, achieving optimal true positive rates frequently necessitates visual inspection and manual adjustments. In the initial phase of this study, hetero‐variants (glycoforms) of a monoclonal antibody were distinguished using liquid chromatography‐mass spectrometry, revealing discernible peaks at the intact level. To comprehensively identify each peak (hetero‐variant) in the intact‐level analysis, a deep learning approach utilizing convolutional neural networks (CNNs) was employed in the subsequent phase of the study. In the current case study, utilizing conventional software for peak identification, five peaks were detected using a 0.5 threshold, whereas seven peaks were identified using the CNN model. The model exhibited strong performance with a probability area under the curve (AUC) of 0.9949, surpassing that of partial least squares discriminant analysis (PLS‐DA) (probability AUC of 0.8041), and locally weighted regression (LWR) (probability AUC of 0.6885) on the data acquired during experimentation in real‐time. The AUC of the receiver operating characteristic curve also illustrated the superior performance of the CNN over PLS‐DA and LWR.